COHANCE Cohance Lifesciences Q4 FY25 results (Jan–Mar 2025) and concall
Management summary
- Cohance Lifesciences (formerly Suven Pharma) completed its formal merger and rebranding, positioning itself as a technology-led CDMO platform.
- While FY25 was a foundational year of integration and strategic acquisitions (NJ Bio, Sapala), the company delivered steady 9% growth.
- Management is guiding for an acceleration in FY26, targeting double-digit revenue growth despite temporary margin pressure from ongoing investments.
Source: Inve concall analysis and management guidance record.
What they filed
| Line item | Q3 FY25 | Q4 FY25 |
|---|---|---|
| Revenue | 676 | 840 |
| EBITDA | 237 | 229 |
| Net profit | 153 | 117 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Guidance & targets
2Revenue
Revenue Growth Revenue · FY26 · Medium confidence in the teens
Margin
EBITDA Margin Margin · FY26 · High confidence low 30s
Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.
Q&A highlights
2Rationale for Sapala and NJ Bio Acquisitions Direct
Rationale for acquisition of Sapala and NJ Bio... we wanted to expand our capabilities on technology and both ADCs and Oligo are fast growing capabilities... investment in these capabilities have allowed us to enter and expand our tab.
Explains the strategic shift toward high-growth, complex modalities like Antibody Drug Conjugates (ADCs) and Oligonucleotides.
Asked by Mehul Panjuani
Commercialization Timeline for Phase-3 Pipeline Partial
But right now the guidance we are giving is one product, four projects getting into commercial and we are hoping that others will also follow soon.
Provides visibility into the near-term revenue conversion of the expanded R&D pipeline.
Asked by Mehul Panjuani
Unlock risks & concerns, Q1 FY26 watchlist, and full call analysis
You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:
- 3 risks, concerns & management red flags
- Watchlist triggers for Q1 FY26
- +2 more guidance targets & verbatim management quotes
- +1 more analyst Q&A exchange & evasion checks
- Full section-by-section call narrative
Sign in to use your monthly call allowance.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image





